Šīs tīmekļa vietnes satura kvalitātes uzlabošanai un pielāgošanai lietotāju vajadzībām tiek lietotas sīkdatnes - tai skaitā arī trešo pušu sīkdatnes. Turpinot lietot šo vietni Jūs piekrītat sīkdatņu lietošanai.
JSC Grindeks extends its product range offering new generation medicine for the treatment of schizophrenia
Emitents Grindeks, AS (5299006DWR32NKWM1O86)
Veids Būtiski notikumi
Valoda EN
Statuss Publicēts
Datums 2007-12-10 14:33:31
Versijas komentārs

From this 10th of December, JSC Grindeks begins to offer Rispaxol® - the qualitative new generation medicine for the treatment of schizophrenia. This medicine will be included in the List of reimbursable medical products of Latvia with its reference price, and from 1 January 2008 schizophrenia patients will have been being reimbursed for purchase expenses of 100%.

Grindeks keeps observing continuously the tendencies on pharmaceutical market, responding to them quickly and actively to offer consumers new medicines necessary to meet their needs.

„I am satisfied with our ability to offer to Latvian market high quality effective product manufactured by domestic producer, and complying with all and any modern international requirements and quality standards. The new medicine will be effective measure in struggling against disastrous disease; furthermore, we have found a possibility to offer it to the state for the most beneficial price. Introduction of Rispaxol® shows Grindeks as a company having obtained considerable achievement in extending its product range,” pointed Jānis Romanovskis, Chairman of the Board of Grindeks.

Perspective development and promotion of generics which will have been carrying out on the market soon after expiration of a patent covering original products, is the one of strategic directions of the Grindeks’s new products development. Rispaxol® is bioequivalent* to the original product Risperidonum, which had been task-oriented created to fight effectively against schizophrenia – one of the gravest mental diseases.

According to the World Health Organization statistical data, schizophrenia is one of the most prevalent insanities, and 1% of the population of the world is affected with it, regardless of economic conditions in the state, irrespective of continent and climate.  The incidence of this disease, diagnosed in Latvia is approximately 19 000**.

Grindeks has intended to start a promotion of Rispaxol® in Russia and countries of Commonwealth of Independent States from 2008.

JSC Grindeks is the leading pharmaceutical company in Baltic States, specializing in the research, development, manufacturing and sales of heart and cardiovascular, central nervous system and anti-cancer medications. A range of Grindeks’s products covers a successful combination of original products and generics, with the original products Mildronate® and Ftorafur® and more than 100 forms of effective and safe generics included therein.

Grindeks concern consists of four subsidiary companies in Latvia, Estonia and Russia as well as ten representative offices. Products of the company are exported to more than 40 countries. Main markets are the Baltic States, Russia and CIS countries, Japan, USA. Grindeks shares are listed in the Official List of Riga Stock Exchange.

 Laila Kļaviņa

Manager of the Communications Department of JSC Grindeks

Phone: 7083370

Mob. phone: 29256012

* If two or more similar dosage forms of a drug reach the general circulation at the same relative rate and the same relative extent, they are bioequivalent

** Sources – The Business Activity Report of State Mental Health Agency  and data base of Central Statistics Board.